Get the Stockscreener App
1.00
0.99%
0.0098
After Hours:
1.01
0.01
+1.00%
Lucid Diagnostics Inc stock is traded at $1.00, with a volume of 821.95K.
It is up +0.99% in the last 24 hours and down -0.99% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.9902
Open:
$0.99
24h Volume:
821.95K
Relative Volume:
0.68
Market Cap:
$190.77M
Revenue:
$4.71M
Net Income/Loss:
$-58.01M
P/E Ratio:
-1.2145
EPS:
-0.8234
Net Cash Flow:
$-46.68M
1W Performance:
-6.54%
1M Performance:
-0.99%
6M Performance:
-15.25%
1Y Performance:
-15.25%
1-Day Range:
$0.9722
$1.01
1-Week Range:
$0.9515
$1.09
52-Week Range:
$0.90
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.00 | 190.77M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics (LUCD) Extends Decline: Approaching Key Support at $0.99 After 3.7% DropKeltner Channel - dars.gov.et
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - GuruFocus
Lucid Diagnostics (LUCD) Edges Higher as Diagnostics Sector Sees Renewed InterestStop Loss Guidance - dars.gov.et
Lucid Diagnostics: Positioned For A Medicare-Driven Inflection (NASDAQ:LUCD) - Seeking Alpha
LUCD News | LUCID DIAGNOSTICS INC (NASDAQ:LUCD) - ChartMill
Lucid Diagnostics Inc.(NasdaqCM:LUCD) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Lucid Diagnostics Inc.(NasdaqCM: LUCD) dropped from Russell 3000 Value Benchmark - marketscreener.com
Lucid Diagnostics Inc.(NasdaqCM: LUCD) dropped from Russell 2500 Value Benchmark - marketscreener.com
Lucid Diagnostics Inc.(NasdaqCM: LUCD) dropped from Russell 2000 Value Benchmark - marketscreener.com
Lucid Diagnostics Inc. Actuals & Estimates (NASDAQ:LUCD) - TradingView
LUCD Forecast — Price Target — Prediction for 2027 - TradingView
Lucid Diagnostics Shareholders Approve Stock Authorization Increase - TipRanks
Lucid Diagnostics (LUCD) boosts authorized shares to 400M and re-elects directors - Stock Titan
LUCD: All proposals passed, including director elections and share authorization increase - TradingView
Transcript : Lucid Diagnostics Inc.Shareholder/Analyst Call - marketscreener.com
Lucid Diagnostics (LUCD) Holds Steady at $1.03: Stock Consolidates Near Key LevelsPre-Earnings Momentum - dars.gov.et
Lucid Diagnostics Inc (LUCD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Top Lucid Diagnostics (LUCD) Competitors 2026 - MarketBeat
Lucid Diagnostics Inc (LUCD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey
Lucid Diagnostics Inc (LUCD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lucid Diagnostics Inc (LUCD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lucid Diagnostics Inc (LUCD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LUCD Q1 2026 Earnings: EPS Misses Estimates by 100.7% as Company Reports No RevenueEarnings Turnaround - dars.gov.et
Certain Stock Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2026. - marketscreener.com
Lucid Diagnostics misses on revenue, but 2026 growth outlook lights up bull case - MSN
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case - Benzinga
LUCD Maintained by Ascendiant Capital -- Price Target Raised to $9.25 - GuruFocus
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results - Yahoo Finance
Lucid Diagnostics Q1 2026 Earnings: EPS Miss Widens as Company Reports Wider-Than-Expected LossManagement Tone Analysis - dars.gov.et
LUCD Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue Stage ChallengesRevenue Warning Signal - The Legal Advocate
LUCD Stock Price, Quote & Chart | LUCID DIAGNOSTICS INC (NASDAQ:LUCD) - ChartMill
LUCDLucid Diagnostics Inc Stock Price and Quote - Finviz
Lucid Diagnostics (LUCD) Surges 7% as Momentum Builds Near Key ResistanceTurnaround Stocks - The Legal Advocate
Lucid Diagnostics Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Firm Advances Commercial Rollout - The Legal Advocate
Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market - Stock Titan
Lucid Diagnostics (LUCD) Rallies +1.30% as Bulls Target $1.02 2026-05-19Dividend Growth Stocks - The Legal Advocate
Lucid Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-05-17 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates - MSN
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ... By GuruFocus - Investing.com Canada
Upcoming Events - FinancialContent
Maxim Group Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
BTIG Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $2.5 - Moomoo
PAVmed (PAVM) Q1 2026 Earnings Transcript - AOL.com
PAVmed (PAVM) Q4 2025 Earnings Transcript - The Globe and Mail
PAVmed Reports Q1 2026 Financial Results, Highlights Progress in Veris Health FDA Submission and Lucid Diagnostics Commercial Expansion - Minichart
Earnings Call Summary | Lucid Diagnostics(LUCD.US) Q1 2026 Earnings Conference - 富途牛牛
PAVmed Reports Wider-than-Expected Q1 2026 Loss - AlphaStreet
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
Aug 20 '25 |
Buy |
1.02 |
100,000 |
101,840 |
665,443 |
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):